Better treatment for stroke patients on horizon

Two molecules may provide, for the first time, an indication of which stroke patients will suffer a further, long-term neurological deficit, allowing doctors to tailor treatment more effectively.

Subarachnoid (SAH), a form of stroke, affects around half a million people worldwide each year. Nearly 50 per cent of patients who survive the initial haemorrhage die within 30 days, with survivors likely to suffer permanent disability.

A study by Dr Sanjaya Kuruppu and Professor Ian Smith of Monash University and clinicians at Harvard Medical School, Dr Mingming Ning and Dr Sherry Chou, has shown that there may be a way to predict the sub-group of SAH patients that will suffer severe .

By assessing the cerebrospinal fluid of SAH patients, the researchers discovered that in the three days immediately following the stroke, an enzyme, endothelin converting enzyme-1 (ECE-1) and its substrate big endothelin-1 (BigET-1) were elevated in patients that suffered a disability that severely impacted on their capacity to self-care.

Dr Sanjaya Kuruppu, of the Monash Department of Biochemistry and Molecular Biology said the discovery was a breakthrough in treating a deadly and unpredictable condition.

"This is the first time doctors have had an early and accurate indication that disability will occur, giving them time to focus appropriate and aggressive therapies on this group of patients," Dr Kuruppu said.

"More importantly, it provides families with information required to make crucial decisions about subsequent long-term care."

As cerebrospinal fluid is routinely monitored following SAH, testing for elevated levels of ECE-1 and BigET-1 would have no negative impact on .

Professor Ian Smith, Pro Vice-Chancellor (Research and Research Infrastructure) was the lead researcher on the project at Monash.

"The next step in bringing this breakthrough to a clinical setting is to develop the technology to enable rapid diagnosis in a hospital setting and we're currently making progress on this," Professor Smith said.

The Monash researchers, again in collaboration with Harvard, are planning a larger clinical study in the near future. They aim to determine the exact threshold level of the molecules required to classify a patient as being at high risk of developing long-term disability.

add to favorites email to friend print save as pdf

Related Stories

Ruptured aneurysm has lasting impact on quality of life

Mar 12, 2013

Ten years after stroke caused by a ruptured aneurysm of the brain, surviving patients have persistent difficulties in several areas affecting quality of life, reports a study in the March issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. ...

What are the long term outcomes following stroke?

May 17, 2011

Despite the recognition of stroke as a major contributor to disability and mortality worldwide, little is known about the long-term outcomes among individuals who survive a stroke. In a research study reported by Charles ...

Recommended for you

An autoimmune response may contribute to hypertension

16 hours ago

High blood pressure is a major risk factor for heart attack, stroke, chronic heart failure, and kidney disease. Inflammation is thought to promote the development of high blood pressure, though it is not clear what triggers ...

Results of RIBS IV trial reported

Sep 16, 2014

A new clinical trial comparing the use of everolimus-eluting stents (EES) and drug-eluting balloons (DEB) in treating in-stent restenosis (ISR) from drug-eluting stents found that EES provided superior late angiographic results ...

Results of DKCRUSH-VI trial reported

Sep 16, 2014

A new study found that fractional flow reserve (FFR)-guided provisional side branch (SB) stenting of true coronary bifurcation lesions yields similar outcomes to the current standard of care. The DKCRUSH-VI clinical trial ...

User comments